Edition:
United Kingdom

Sellas Life Sciences Group Inc (SLS.OQ)

SLS.OQ on NASDAQ Stock Exchange Capital Market

1.56USD
19 Oct 2018
Change (% chg)

$-0.24 (-13.33%)
Prev Close
$1.80
Open
$1.77
Day's High
$1.90
Day's Low
$1.55
Volume
510,509
Avg. Vol
157,446
52-wk High
$11.82
52-wk Low
$0.80

Latest Key Developments (Source: Significant Developments)

Sellas Says Independent Experts Confirmed Interim Analysis Of Mid-Stage NeuVax Trial
Friday, 19 Oct 2018 

Oct 19 (Reuters) - Sellas Life Sciences Group Inc ::DATA SAFETY MONITORING BOARD CONFIRMS TRIPLE NEGATIVE BREAST CANCER AS THE TARGET PATIENT POPULATION FOR DEVELOPMENT OF NEUVAX™ (NELIPEPIMUT-S) IN COMBINATION WITH TRASTUZUMAB (HERCEPTIN®) IN HER2 1+/2+ BREAST CANCER PATIENTS FOLLOWING FINAL ANALYSIS OF PHASE 2B TRIAL.SELLAS LIFE SCIENCES - FINAL ANALYSIS SHOWED NO NEW SAFETY SIGNALS, SHOWED NO DIFFERENCE IN CARDIOTOXICITY BETWEEN TZ + NPS COMPARED TO TZ ALONE.SELLAS LIFE SCIENCES - DATA SAFETY MONITORING BOARD CONCLUDED FINAL DATA FROM PHASE 2B STUDY OF TRASTUZUMAB CONFIRMS PREVIOUSLY ANNOUNCED FINDINGS.SELLAS LIFE SCIENCES GROUP INC - DSMB CONCLUDED THAT THERE WAS AN INCREMENTAL IMPROVEMENT IN OUTCOMES AND STATISTICS WITH A LONGER MEDIAN FOLLOW-UP.  Full Article

Sellas Life Sciences Q2 Loss Per Share $1.26
Wednesday, 15 Aug 2018 

Aug 15 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES PROVIDES BUSINESS UPDATE AND REPORTS SECOND QUARTER 2018 FINANCIAL RESULTS.Q2 LOSS PER SHARE $1.26.AS OF JUNE 30, 2018, CASH AND CASH EQUIVALENTS WERE $1.3 MILLION.  Full Article

Sellas Life Sciences Group Files For Offering Of Up To 9.4 Mln Shares
Thursday, 19 Jul 2018 

July 19 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO 9.4 MILLION SHARES OF CO'S COMMON STOCK BY SELLING STOCKHOLDERS - SEC FILING.  Full Article

Empery Asset Management Lp Reports 9.99 pct Passive Stake In Sellas Life Sciences Group Inc As Of July 12
Wednesday, 18 Jul 2018 

July 18 (Reuters) - Sellas Life Sciences Group Inc ::EMPERY ASSET MANAGEMENT, LP REPORTS 9.99 PERCENT PASSIVE STAKE IN SELLAS LIFE SCIENCES GROUP INC AS OF JULY 12, 2018 - SEC FILING.  Full Article

Sellas Life Sciences Says Offering Of 6.08 Mln Shares
Tuesday, 26 Jun 2018 

June 26 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP INC SAYS OFFERING OF 6.08 MILLION SHARES OF CO'S COMMON STOCK - SEC FILING.  Full Article

Galena Biopharma posts Q3 loss $0.15/shr from continuing operations
Thursday, 9 Nov 2017 

Nov 9 (Reuters) - Galena Biopharma Inc :Galena Biopharma reports third quarter 2017 financial results.Q3 loss per share $0.15 from continuing operations.Galena Biopharma Inc - ‍cash and cash equivalents of approximately $12.9 million as of September 30, 2017, compared with $18.1 million as of December 31, 2016​.  Full Article

Galena Biopharma says co and Cardinal Health entered into a settlement relating to product swap agreement​
Wednesday, 18 Oct 2017 

Oct 19 (Reuters) - Galena Biopharma Inc :Galena Biopharma Inc says on October 12, co and Cardinal Health entered into a settlement relating to product swap agreement​ - SEC filing.Galena Biopharma Inc - ‍pursuant to agreement , co, Cardinal agreed to resolve all of their outstanding disputes over a product swap agreement​.Galena Biopharma Inc - ‍Cardinal will destroy all of zuplenz oral soluble film that is returned as a result of product swap agreement.Galena Biopharma Inc - ‍product swap agreement with Cardinal will be terminated as of effective date of agreement​.  Full Article

Galena Biopharma appoints Stephen Ghiglieri as CFO
Thursday, 3 Nov 2016 

Galena Biopharma Inc : Galena biopharma - Stephen Ghiglieri has been appointed as company's executive vice president and chief financial officer, effective immediately .Galena biopharma appoints Stephen F. Ghiglieri as executive vice president and chief financial officer.  Full Article

BRIEF-Sellas Life Sciences Files For Offering Of Up To $30 Mln

* SELLAS LIFE SCIENCES GROUP INC FILES FOR OFFERING OF UP TO $30 MILLION - SEC FILING Source text: (https://bit.ly/2klt2uI) Further company coverage: